Citations

Showing 10 of 107868 citations.

Insulin Sensitivity Does Not Account for Differences in Type 2 Diabetes Incidence Between San Antonio, Texas and Mexico City, Mexico
Burke, J. P., Williams, Ken, Haffner, Steven M., Villalpando, Clicerio González, Stern, Michael P.

Mayo Clinic

Diabetes Care | March 5, 2007 | Volume: 25 | Issue: 5 | Pages: 938-939

10.2337/diacare.25.5.938 Get It

Posttransplantation Diabetes
Basu, Ananda , Erwin, Patricia J., Velosa, Jorge A., Gabriel, Sherine E., Kudva, Yogish C. , Montori, Víctor M.

Mayo Clinic

Diabetes Care | March 5, 2007 | Volume: 25 | Issue: 3 | Pages: 583-592

10.2337/diacare.25.3.583 | PMID 11874952 Get It

OBJECTIVES— To systematically review the incidence of posttransplantation diabetes (PTD), risk factors for its development, prognostic implications, and optimal management.RESEARCH DESIGN AND METHODS— We searched databases (MEDLINE, EMBASE, the Cochrane Library, and others) from inception to September 2000, reviewed bibliographies in reports retrieved, contacted transplantation experts, and reviewed specialty journals. Two reviewers independently determined report inclusion (original studies, in all languages, of PTD in adults with no history of diabetes before transplantation), assessed study methods, and extracted data using a standardized form. Meta-regression was used to explain between-study differences in incidence.RESULTS— Nineteen studies with 3,611 patients were included. The 12-month cumulative incidence of PTD is lower (<10% in most studies) than it was 3 decades ago. The type of immunosuppression explained 74% of the variability in incidence (P = 0.0004). Risk factors were patient age, nonwhite ethnicity, glucocorticoid treatment for rejection, and immunosuppression with high-dose cyclosporine and tacrolimus. PTD was associated with decreased graft and patient survival in earlier studies; later studies showed improved outcomes. Randomized trials of treatment regimens have not been conducted.CONCLUSIONS— Physicians should consider modification of immunosuppressive regimens to decrease the risk of PTD in high-risk transplant recipients. Randomized trials are needed to evaluate the use of oral glucose-lowering agents in transplant recipients, paying particular attention to interactions with immunosuppressive drugs.
Angioneurotic Edema as a Side Effect of Pioglitazone
Shadid, Samiah, Jensen, Michael D.

Mayo Clinic

Diabetes Care | March 5, 2007 | Volume: 25 | Issue: 2 | Pages: 405-405

10.2337/diacare.25.2.405 | PMID 11815525 Get It

Comment on study by Perkins et al.
Stevens, J. Clarke, Harper, C. Michel

Mayo Clinic

Diabetes Care | March 5, 2007 | Volume: 25 | Issue: 12 | Pages: 2362-2362

10.2337/diacare.25.12.2362 | PMID 12453995 Get It

Personal Control and Disordered Eating in Female Adolescents With Type 1 Diabetes
Schwartz, Stefanie A., Weissberg‐Benchell, Jill , Perlmuter, Lawrence C.

Mayo Clinic

Diabetes Care | March 5, 2007 | Volume: 25 | Issue: 11 | Pages: 1987-1991

10.2337/diacare.25.11.1987 | PMID 12401744 Get It

OBJECTIVE—The onset and subsequent management of diabetes can challenge one’s sense of control. Sense of control can also be affected by the biological changes accompanying normal pubertal development. The negative impact on one’s sense of control may be further exacerbated when both events (i.e., diabetes and puberty) occur in relatively close temporal proximity. RESEARCH DESIGN AND METHODS—This study examined the relationship between sense of control and disordered eating and glycemic control in 45 female adolescents with type 1 diabetes. RESULTS—A lower sense of overall control and a lower sense of bodily control were both directly related to more severe eating-disordered symptoms. However, a lower sense of overall control and lower bodily control were related to poorer metabolic control primarily when the diagnosis of diabetes occurred closer to the onset of puberty. CONCLUSIONS—Clinicians should assess and monitor perceptions of control and also consider the temporal proximity of disease onset and onset of puberty when managing type 1 diabetes in female adolescents.
The Impact of Planned Care and a Diabetes Electronic Management System on Community-Based Diabetes Care
Montori, Víctor M. , Dinneen, Seán F. , Gorman, Colum A., Zimmerman, Bruce R., Rizza, Robert A., Bjornsen, Susan S., Bryant, Sandra C. , Smith, Steven A., Group, for The Translation Project Investigator, Green, Erin M. , Group, for The Translation Project Investigator, Montori, Victor M , Dinneen, Sean F

Mayo Clinic

Diabetes Care | March 5, 2007 | Volume: 25 | Issue: 11 | Pages: 1952-1957

10.2337/diacare.25.11.1952 | PMID 12401738 Get It

OBJECTIVE—The Mayo Health System Diabetes Translation Project sought to assess models of community-based diabetes care and use of a diabetes electronic management system (DEMS). Planned care is a redesigned model of chronic disease care that involves guideline implementation, support of self-management, and use of clinical information systems. RESEARCH DESIGN AND METHODS—We studied adult diabetic patients attending three primary care practice sites in Wisconsin and Minnesota. We implemented planned care at all sites and DEMS in the practice of 16 primary care providers. We assessed quality of diabetes care using standard indicators for 200 patients randomly selected from each site at baseline and at 24 months of implementation. We used multivariable analyses to estimate the association between planned care and DEMS and each quality indicator. RESULTS—Planned care was associated with improvements in measurement of HbA1c (odds ratio 7.0 [95% CI 4.2–11.6]), HDL cholesterol (5.6 [4.1–7.5]), and microalbuminuria (5.3 [3.5–8.0]), as well as the provision of tobacco advice (6.9 [4.7–10.1]), among other performance measures. DEMS use was associated with improvements in all indicators, including microalbuminuria (3.2 [1.9–5.2]), retinal examination (2.4 [1.5–3.9]), foot examinations (2.3 [1.2–4.4]), and self-management support (2.6 [1.7–3.8]). Although planned care was associated with improvements in metabolic control, we observed no additional metabolic benefit when providers used DEMS. CONCLUSIONS—Planned care was associated with improved performance and metabolic outcomes in primary care. DEMS use augmented the impact of planned care on performance outcomes but not on metabolic outcomes. Optimal identification of the best translation of evidence to diabetes practice will require longer follow-up or new care-delivery models.
“Diabetic Mastopathy,” or Sclerosing Lymphocytic Lobulitis, Is Strongly Associated With Type 1 Diabetes
Kudva, Yogish C. , Reynolds, Carol, Powell, Claudia, Oberg, Ann L. , Crotty, Thomas B., O’Brien, Timothy

Mayo Clinic

Diabetes Care | March 5, 2007 | Volume: 25 | Issue: 1 | Pages: 121-126

10.2337/diacare.25.1.121 | PMID 11772912 Get It

OBJECTIVE—To demonstrate the strong association of diabetic mastopathy or sclerosing lymphocytic lobulitis with type 1 diabetes mellitus by studying appropriate control groups and to describe risk factors and natural history of the disorder. RESEARCH DESIGN AND METHODS—This was a retrospective cross-sectional study of four groups of patients conducted at a setting tertiary care medical center. We examined benign breast biopsies (investigator masked to identity) from age-matched patients with types 1 and 2 diabetes, autoimmune thyroid disease, or none of the above disorders for sclerosing lymphocytic lobulitis. Several risk factors proposed for the disorder (age at diagnosis of benign breast disease, duration of diabetes, age at onset of diabetes, prevalence of retinopathy, neuropathy, nephropathy and cheiroarthropathy, glycemic control, parity, oral contraceptive use, menopausal status, or number of breast biopsies) were evaluated, and patients were contacted to describe the natural history of the disorder. RESULTS—Sclerosing lymphocytic lobulitis was identified in 69.7% of the subjects with type 1 diabetes and 1.8% of those with autoimmune thyroid disease diagnosed with benign breast disease at surgery. It did not occur in patients with type 2 diabetes with or without insulin treatment or in control subjects. Only retinopathy and peripheral neuropathy were associated with sclerosing lymphocytic lobulitis. Breast carcinoma or lymphoma did not occur subsequently in any type 1 diabetes patient with or without sclerosing lymphocytic lobulitis. CONCLUSIONS—Sclerosing lymphocytic lobulitis is strongly associated with type 1 diabetes. Retinopathy and neuropathy are associated with the disorder. The risk of malignancy is not increased.
Temporal Trends in BMI Among Adults With Diabetes
Leibson, Cynthia L., Williamson, David F., Melton, L. Joseph, Smith, Steven A., Ransom, Jeanine E. , Schilling, Peter L. , Narayan, K.M. Venkat , Palumbo, Pasquale J

Mayo Clinic

Diabetes Care | March 5, 2007 | Volume: 24 | Issue: 9 | Pages: 1584-1589

10.2337/diacare.24.9.1584 | PMID 11522703 Get It

OBJECTIVE—Increasing obesity within the general population has been accompanied by rising rates of diabetes. The extent to which obesity has increased among people with diabetes is unknown, as are the potential consequences for diabetes outcomes. RESEARCH DESIGN AND METHODS—Community medical records (hospital and ambulatory) of all Rochester, Minnesota, residents aged ≥30 years who first met standardized research criteria for diabetes from 1970 to 1989 (n = 1,306) were reviewed to obtain data on BMI and related characteristics as of the diabetes identification date (±3 months). Vital status as of 31 December 1999 and date of death for those who died were obtained from medical records, State of Minnesota death tapes, and active follow-up. RESULTS—As of the identification date, data on BMI were available for 1,290 cases. Of the 272 who first met diabetes criteria in 1970–1974, 33% were obese (BMI ≥30), including 5% who were extremely obese (BMI ≥40). These proportions increased to 49% (P < 0.001) and 9% (P = 0.012), respectively, for the 426 residents who first met diabetes criteria in 1985–1989. BMI increased significantly with increasing calendar year of diabetes identification in multivariable regression analysis. Analysis of survival revealed an increased hazard of mortality for BMI ≥41, relative to BMI of 23–25 (hazard ratio 1.60, 95% CI 1.09–2.34, P = 0.016). CONCLUSIONS—The prevalence of obesity and extreme obesity among individuals at the time they first met criteria for diabetes has increased over time. This is disturbing in light of the finding that diabetic individuals who are extremely obese are at increased risk of mortality compared with their nonobese diabetic counterparts.
Elevated Incidence of Type 2 Diabetes in San Antonio, Texas, Compared With That of Mexico City, Mexico
Burke, J. P., Williams, Ken, Haffner, Steven M., Villalpando, Clicerio González, Stern, Michael P.

Mayo Clinic

Diabetes Care | March 5, 2007 | Volume: 24 | Issue: 9 | Pages: 1573-1578

10.2337/diacare.24.9.1573 | PMID 11522701 Get It

OBJECTIVE—To compare the incidence of type 2 diabetes between low-income Mexican-Americans residing in San Antonio, Texas, and low-income residents in Mexico City, Mexico. RESEARCH DESIGN AND METHODS—Using data from the San Antonio Heart Study and the Mexico City Diabetes Study, we compared the incidence of type 2 diabetes in 35- to 64-year-old low-income Mexican-American residents of San Antonio with similarly aged low-income residents of Mexico City. Because of the different follow-up times in the two studies, Poisson regression was used to compare the rates of diabetes. Potential risk factors for diabetes were also analyzed to determine whether they explained or contributed to a difference in incidence. RESULTS—The age- and sex-adjusted incidence of type 2 diabetes was significantly higher in San Antonio (RR 2.01) compared with Mexico City. This difference was seen primarily in the oldest age group (55–64 years of age) and remained statistically significant after adjusting for a number of diabetes risk factors, including demographic, anthropometric, and metabolic variables. Follow-up rates were similar in both cities. CONCLUSIONS—We conclude that there was a higher incidence of type 2 diabetes in San Antonio than in Mexico City, and that difference occurred primarily in individuals in the oldest age group. The potential mediating factors we examined did not account for this difference. Other factors, such as exercise and diet, which were not available for analysis in this study, in addition to a cohort effect, may have contributed to the difference in incidence of type 2 diabetes in the two cities. In addition, there was no evidence of a higher case fatality among diabetic individuals from Mexico City compared with San Antonio.
Screening Mammogram Utilization in Women With Diabetes
Beckman, Thomas J. , Cuddihy, Robert , Scheitel, Sidna M., Naessens, James M. , Killian, Jill M. , Pankratz, V. Shane , Cuddihy, Robert M

Mayo Clinic

Diabetes Care | March 5, 2007 | Volume: 24 | Issue: 12 | Pages: 2049-2053

10.2337/diacare.24.12.2049 | PMID 11723081 Get It

OBJECTIVE—To determine whether women with diabetes undergo fewer screening mammograms than matched control subjects.RESEARCH DESIGN AND METHODS—A total of 424 women with diabetes aged 50–75 years who received their primary care from general internists at a large Midwestern multispecialty group practice were retrospectively studied for frequency of mammography from August 1997 to January 2000. Two control subjects without diabetes (n = 845) were matched to each case by age, sex, provider, and date of visit. The main outcome measure was the percentage of subjects undergoing mammography 1 year before and 30 days after an index date, defined as the most recent health care visit after August 1997 and before January 2000.RESULTS—Analysis by conditional logistic regression demonstrated that women with diabetes had significantly lower rates of mammograms than control subjects (78.1 vs. 84.9%, respectively; odds ratio 0.63, P = 0.002). After adjusting for insurance status and race, women with diabetes continued to have significantly lower rates of mammography (odds ratio 0.70, P = 0.027).CONCLUSIONS—Women with diabetes were significantly less likely to undergo screening mammography than control subjects. Considering the increasing incidence of diabetes and the equal incidence of malignancy in women with and without diabetes, it would be beneficial to improve breast cancer screening in this population.